Identification of differentially expressed microRNAs in human male breast cancer

BackgroundThe discovery of small non-coding RNAs and the subsequent analysis of microRNA expression patterns in human cancer specimens have provided completely new insights into cancer biology. Genetic and epigenetic data indicate oncogenic or tumor suppressor function of these pleiotropic regulators. Therefore, many studies analyzed the expression and function of microRNA in human breast cancer, the most frequent malignancy in females. However, nothing is known so far about microRNA expression in male breast cancer, accounting for approximately 1% of all breast cancer cases.MethodsThe expression of 319 microRNAs was analyzed in 9 primary human male breast tumors and in epithelial cells from 15 male gynecomastia specimens using fluorescence-labeled bead technology. For identification of differentially expressed microRNAs data were analyzed by cluster analysis and selected statistical methods.Expression levels were validated for the most up- or down-regulated microRNAs in this training cohort using real-time PCR methodology as well as in an independent test cohort comprising 12 cases of human male breast cancer.ResultsUnsupervised cluster analysis separated very well male breast cancer samples and control specimens according to their microRNA expression pattern indicating cancer-specific alterations of microRNA expression in human male breast cancer. miR-21, miR519d, miR-183, miR-197, and miR-493-5p were identified as most prominently up-regulated, miR-145 and miR-497 as most prominently down-regulated in male breast cancer.ConclusionsMale breast cancer displays several differentially expressed microRNAs. Not all of them are shared with breast cancer biopsies from female patients indicating male breast cancer specific alterations of microRNA expression.

[1]  V. Barak,et al.  [Male breast cancer]. , 1989, Harefuah.

[2]  Leonard D. Goldstein,et al.  MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype , 2007, Genome Biology.

[3]  Jinghuan Li,et al.  Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma , 2009, Modern Pathology.

[4]  M. D'Esposito,et al.  An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation , 2009, Oncogene.

[5]  G. Kristiansen,et al.  Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma , 2009, International journal of cancer.

[6]  C. Eng,et al.  A limited set of human MicroRNA is deregulated in follicular thyroid carcinoma. , 2006, The Journal of clinical endocrinology and metabolism.

[7]  S. D. Selcuklu,et al.  miR-21 as a key regulator of oncogenic processes. , 2009, Biochemical Society transactions.

[8]  I. Ellis,et al.  MicroRNA involvement in the pathogenesis and management of breast cancer , 2009, Journal of Clinical Pathology.

[9]  K. Mimori,et al.  Over- and under-expressed microRNAs in human colorectal cancer. , 2009, International journal of oncology.

[10]  A. Ganser,et al.  Aberrant methylation and impaired expression of the p15INK4b cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML) , 2003, Leukemia.

[11]  John D. Minna,et al.  miR-93, miR-98, and miR-197 Regulate Expression of Tumor Suppressor Gene FUS1 , 2009, Molecular Cancer Research.

[12]  Constance Scharff,et al.  FOXP2 as a molecular window into speech and language. , 2009, Trends in genetics : TIG.

[13]  Hailong Wu,et al.  p53 represses c-Myc through induction of the tumor suppressor miR-145 , 2009, Proceedings of the National Academy of Sciences.

[14]  Stefano Volinia,et al.  MicroRNA expression profiling of male breast cancer , 2009, Breast Cancer Research.

[15]  A. Krogh,et al.  Programmed Cell Death 4 (PDCD4) Is an Important Functional Target of the MicroRNA miR-21 in Breast Cancer Cells* , 2008, Journal of Biological Chemistry.

[16]  C. Perou,et al.  Cytokeratin profiles of male breast cancers , 2006, Histopathology.

[17]  U. Lehmann,et al.  One-step extraction of RNA from archival biopsies. , 2001, Analytical biochemistry.

[18]  Jean-Baptiste Cazier,et al.  Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia , 2008, PloS one.

[19]  G. Braunstein,et al.  Clinical practice. Gynecomastia. , 2007, The New England journal of medicine.

[20]  W. Cho,et al.  Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. , 2009, European journal of cancer.

[21]  C. Croce,et al.  MicroRNA gene expression deregulation in human breast cancer. , 2005, Cancer research.

[22]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[23]  F. Noubissi,et al.  CRD-BP protects the coding region of betaTrCP1 mRNA from miR-183-mediated degradation. , 2009, Molecular cell.

[24]  L. Brinton,et al.  Is Male Breast Cancer Similar or Different than Female Breast Cancer? , 2004, Breast Cancer Research and Treatment.

[25]  U. Lehmann,et al.  Reliable microRNA profiling in routinely processed formalin-fixed paraffin-embedded breast cancer specimens using fluorescence labelled bead technology , 2008, BMC biotechnology.

[26]  Qiong Shao,et al.  MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. , 2008, RNA.

[27]  Tongbin Li,et al.  miRecords: an integrated resource for microRNA–target interactions , 2008, Nucleic Acids Res..

[28]  Agnieszka Bronisz,et al.  Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. , 2008, Cancer research.

[29]  H. Müller-Hermelink,et al.  Tissue array technology for testing interlaboratory and interobserver reproducibility of immunohistochemical estrogen receptor analysis in a large multicenter trial. , 2002, American journal of clinical pathology.

[30]  G. Yousef,et al.  Kallikreins as microRNA targets: an in silico and experimental-based analysis , 2008, Biological chemistry.

[31]  D. Steinemann,et al.  Comprehensive genetic and functional characterization of IPH‐926: a novel CDH1‐null tumour cell line from human lobular breast cancer , 2009, The Journal of pathology.

[32]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.